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O B J E C T I V E S The aim of this study was to investigate whether the maximum standardized uptake
value (max SUV) of 18F-ﬂuorodeoxyglucose (FDG)-positron emission tomography (PET)/computed
tomography (CT) provides a quantitative indication of disease activity in Takayasu arteritis (TA) cases.
B A C KG ROUND The clinical value of FDG-PET for assessing TA has been investigated. Clinical
evaluation of disease activity is often difﬁcult, because most patients develop recurrent inﬂammation
while receiving corticosteroid treatment.
METHOD S Thirty-nine TA patients underwent FDG-PET/CT at Tokyo Medical and Dental University
from 2006 to 2010 (35 women and 4 men; median age, 30 years). Disease activity was deﬁned according
to National Institutes of Health criteria. Biomarkers including C-reactive protein and erythrocyte
sedimentation rate were measured. Forty subjects without vasculitis served as control subjects.
R E S U L T S The max SUV was signiﬁcantly higher in active than in inactive cases and control subjects
(active [n  27], median value, 2.7 vs. inactive [n  12], 1.9; control [n  40], 1.8; p  0.001 each). Given
a max SUV cutoff of 2.1, sensitivity for active-phase TA was 92.6%, speciﬁcity 91.7%, positive predictive
value 96.2%, and negative predictive value 84.6%. In receiver-operating characteristic curves compari-
son, max SUV was superior to C-reactive protein (p  0.05) and erythrocyte sedimentation rate (p 
0.05). Max SUV was signiﬁcantly higher in relapsing on treatment cases (n  17) than in stable on
treatment cases (n  12) (median value, 2.6 vs. 1.9; p  0.001).
CONC L U S I O N S FDG-PET/CT is useful for detection of active inﬂammation not only in patients
with active TA before treatment but also in relapsing patients receiving immunosuppressive agents. The
max SUV is useful for assessing subtle activity of TA with high sensitivity. (J Am Coll Cardiol Img 2012;
5:422–9) © 2012 by the American College of Cardiology Foundation
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akayasu arteritis (TA) is a chronic vasculitis,
mainly involving large vessels, including the
aorta, pulmonary artery, and their major
branches (1). Major diagnostic criteria used by
he American College of Rheumatology include
linical symptoms caused by inflammatory or ste-
otic lesions in these arteries (2). Another impor-
ant aspect of TA is the chronic inflammatory
ature of this disease. Disease activity is assessed
ith National Institutes of Health (NIH) criteria
n the basis of 4 elements of clinical status (3).
Even in patients receiving corticosteroid treatment,
ecurrences are common. Estimation of disease activ-
ty in TA patients, particularly those receiving treat-
ents, is a significant clinical management issue.
rythrocyte sedimentation rate (ESR) and C-reactive
rotein (CRP) are the biological markers generally
sed to assess disease activity in TA patients. How-
ver, these markers do not allow differentiation be-
ween active and inactive TA, because they are non-
pecific inflammatory markers (4).
Research has focused particularly on the diagnos-
ic role of 18F-fluorodeoxyglucose (FDG)-positron
mission tomography (PET) in patients with TA,
ecause this modality can estimate the degree as well
s the site of inflammation (5,6). Meller et al. (7)
eported that FDG-PET is more reliable than mag-
etic resonance (MR) imaging for monitoring disease
ctivity during immunosuppressive therapy. In addition,
he maximum standardized uptake value (max
UV) increases as inflammatory reactions spread,
nd max SUV can thus serve as a quantitative
arker of FDG uptake. However, problems with
tudies using FDG-PET include study designs for
etermining activity in TA and low sensitivity for
iagnosing TA (8).
Thus, the diagnostic utility of max SUV from
DG-PET has not been established. Therefore, we
nvestigated whether max SUV, as a quantitative
arker, can be used to determine TA activity in a
elatively large number of patients in a single center.
The first aim of this study was to compare the
ccuracies of max SUV, CRP, and ESR for assess-
ng disease activity in TA. The second aim was to
nvestigate whether max SUV of FDG-PET/
omputed tomography (CT) can serve as an activity
arker in patients with recurrent TA being treated
ith steroids or other immunosuppressants.
M E T H O D S
Study patients. The consecutive TA cases that un-
erwent FDG-PET/CT at Tokyo Medical andental University from 2006 to 2010 were retro-
pectively reviewed. Forty TA patients and 40
ontrol subjects without vasculitis were enrolled.
ne TA patient was excluded, because infectious
isease was noted when FDG-PET/CT was per-
ormed. The 39 TA cases (35 women, 4 men;
edian age, 30 years; range, 13 to 71 years) under-
ent FDG-PTE/CT for diagnosis or clinical needs
ith suspicion of recurrence. The TA had been
iagnosed with American College of Rheumatology
riteria in all cases (2). We also diagnosed patients
ith the Guideline for Management of Vasculitis
yndromes (Japanese Circulation Society 2008) (9),
ncluding the criteria of the Ministry of Health,
abour and Welfare of Japan. We gener-
lly used the latter criteria in clinical diag-
osis. In this study, we confirmed TA
atients satisfied with both of the 2 diag-
ostic criteria. The 40 control subjects (36
omen, 4 men; median age, 38 years;
ange, 13 to 70 years) were selected by sex
nd age as a case-matched study popula-
ion. Thirty-one control subjects had ma-
ignant diseases in remission after therapy
nd underwent FDG-PET/CT to assess
ecurrence. The other 9 subjects were
ealthy and underwent FDG-PET/CT
or cancer screening. All of these subjects
howed no evidence of inflammation or
asculitis, and FDG-PET showed nega-
ive study.
The study protocol was approved by the
nstitutional ethics review committee of
okyo Medical and Dental University. All
atients provided informed consent and
greed to the use of their data for this
tudy.
Disease activity. We assessed disease ac-
tivity by adopting NIH criteria (3),
which define clinical status on the basis
of 4 elements: systemic features, elevated ESR,
vascular ischemia, and angiographic changes. The
active phase is defined as new onset or worsening
of 2 or more of these features. The NIH criteria
were scored within 1 month before or after
FDG-PET/CT.
In all 39 cases, serum CRP and ESR levels were
measured and recorded within 3 days of FDG-
PET/CT. We divided active cases into 2 groups:
untreated cases, and relapsing on treatment cases.
Untreated cases were defined as active TA patients
without previous treatment with steroid or immu-
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424defined as those showing clinical worsening of 2 or
more NIH criteria while receiving therapy and
diagnosed as recurrence. All of the inactive cases
were defined as stable on treatment cases in this
analysis.
To determine the angiographic features for the
NIH criteria, we assessed the findings of stenosis
or dilation by MR angiography. If MR angiog-
raphy data had not been obtained, computed
tomography angiography (CTA) findings were
used. Imaging data were assessed within 1 month
before or after FDG-PET/CT. Imaging data at
diagnosis was used for the scoring of untreated
cases. We performed imaging tests more than
twice, and the data were compared in patients
with relapsing on treatment cases and stable on
treatment cases.
FDG-PET/CT. All FDG-PET/CT scans were per-
formed with Aquiduo (Toshiba Medical, Tokyo,
Japan). The CT data were obtained in 2-mm slices
with a 15° helical pitch, at 120 kV and 50 to 100
mA. Imaging data from CT comprised a matrix of
512  512 pixels. Patients were fasted more than
4 h, and their oral hydration and bladder emptying
were completed before collecting PET/CT data.
The CT data for attenuation correction and ana-
tomical co-registration were obtained during expi-
stics of TA Patients
Active
(n  27)
Inactive
(n  12)
Control
(n  40) p Value
23 12 36 NS
27 (19–40) 51 (28–59) 38 (28–47) NS
3.0 (2–4) 1 (1–1) n/a 0.001
89 (84–95) 98(89–109) 91 (83–98) NS
62 (60–65) 63 (60–70) 67 (60–74) NS
1.6 (1.3–1.8) 1.5 (1.5–1.7) 1.5 (1.3–1.8) NS
2.7 (2.3–3.2) 1.9 (1.8–1.9) 1.8 (1.6–2.0) 0.001
1.0 (0.4–5.6) 0.1 (0.1–0.4) n/a 0.001
40 (18–70) 19 (9–30) n/a 0.001
h to 75th percentile).
ein; ESR  erythrocyte sedimentation rate; IVC  inferior vena cava; max 
nal Institutes of Health; SUV  standardized uptake value; TA  Takayasu
ns of Therapy Among the 3 TA Groups
Untreated
(n  10)
Relapsing on
Treatment
(n  17)
Stable on
Treatment
(n  12) p Value
8 15 12 NS
g) n/a 10 (6–16) 8 (2–15) NS
n/a 29.4% 25% NS
dose are presented as median, (25th to 75th percentile).
s.ratory breath-holding. Contrast media were not
used. After CT scanning, patients were intrave-
nously injected with 3.7 MBq/kg of FDG. A
whole-body scan was performed on all patients 60
min after FDG injection. The PET data were
obtained in 3-dimensional mode for 2 min in each
bed position, for a total of 14 to 16 min. The PET
data consisted of a matrix of 128  128 pixels.
Visual qualitative and semi-quantitative analyses of
PET images. Data from FDG-PET/CT were ana-
yzed by 2 nuclear medical radiologists blinded to
he clinical data. The radiologists assessed focal
ptake in the arterial wall as an inflammatory lesion
f active TA. A region of interest was measured in
he lesion, and max SUV was defined as the highest
alue in this area. Finally, highest max SUV in the
rteries was defined in each case. In cases without
ignificant uptake of FDG, arterial max SUV was
efined as the highest value in a slice-by-slice
nalysis of the entire aorta. Blood pooling in the
umen was excluded when measuring uptake in
he region of interest. Mean SUV was measured
n the center of the inferior vena cava in all cases,
nd target/background ratio was calculated as
ax SUV in arterial wall/mean SUV in inferior
ena cava.
Statistical analysis. Categorical data are presented
as numbers (percentages), and continuous data
are presented as median value and quartile (25%
to 75%). We performed Kruskal–Wallis 1-way
analysis of variance for comparison among 3
groups. Moreover, nonparametric statistics by
Mann–Whitney–Wilcoxon with Holm correction
was used to compare 2 groups. The 95% confi-
dence intervals were calculated, and values of p 
0.05 were considered statistically significant. Sta-
tistical analysis was performed with SPSS soft-
ware (version 11.0.1J, SPSS, Inc., Chicago, Illi-
nois). Area under the curve (AUC) was calculated
for the receiver-operating characteristic (ROC)
curve to determine optimal cutoff values and to
compare the markers. With drawing ROC curve,
the point that is closest to the point of 100%
sensitivity and 100% specificity on the ROC
curve defines cutoff value according to the stan-
dard method. MedCalc software (version 11.4,
MedCalc Software, Mariakerke, Belgium) was
used for statistical comparisons of ROC curves.
Sensitivity (SE), specificity (SP), positive predic-
tive value (PPV), and negative predictive value
(NPV) were determined for the relevant cutoff
values. Statistical correlation was determined byTable 1. Characteri
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425R E S U L T S
Twenty-seven cases were classified as active, and 12
were classified as inactive (Tables 1, 2, and 3). The
max SUV was significantly higher in active than in
inactive cases (p  0.001) (Table 1) and control
subjects (median value, 1.8; p  0.001) (Fig. 1,
eft). The target/background ratio was also signifi-
antly higher in active (median value, 1.7 [1.3 to
.9]) than in inactive cases (median value, 1.1 [1.0
o 1.1]; p  0.001) and control subjects (median
alue, 1.1 [0.9 to 1.2], p  0.001) (Fig. 1, right).
nactive and control cases did not differ significantly
n terms of either max SUV in arterial wall and
arget/background ratio.
Levels of CRP and ESR were significantly higher
n the active than in the inactive cases (Table 1).
Imaging data were obtained in 37 cases by MR
ngiography and in 2 cases by CTA. Progression of
tenosis or dilation of vessels was observed in the
ajority of relapsing cases with these modalities.
o inactive cases showed any significant changes.
Comparisons among utilities of max SUV, CRP, and ESR
for determining active phase TA. With ROC curve,
e determined the cutoff value for these markers
max SUV 2.1; CRP 0.2 mg/dl; ESR 19
m/h). With this cutoff for max SUV, SE for
ctive-phase TA was 92.6%, SP was 91.7%, PPV
as 96.2%, and NPV was 84.6%. As for CRP, SE
or active-phase TA was 81.5%, SP was 66.7%,
PV was 84.6%, and NPV was 61.5%. As for ESR,
E for active-phase TA was 74.1%, SP was 58.3%,
PV was 80%, and NPV was 50%.
Comparisons of ROC curves showed AUC to be
5.4% for max SUV, 84.7% for CRP, and 72.7% for
SR. Max SUV was superior to CRP (p  0.0283)
nd ESR (p  0.0033) in terms of ROC curve
6
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1
M
ax
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p<0.001
p<0.001 n.s.
Figure 1. Comparisons of Max SUV and TBR Among Active, Ina
The maximum standardized uptake value (max SUV) (left) and targ
higher than those in inactive and control cases.nalysis for determining active phase disease with
tatistical significance (Fig. 2, left).
Comparisons among untreated, relapsing on treat-
ment, and stable on treatment TA patients. The 27
active cases were divided into 10 untreated cases
and 17 cases with relapsing on treatment. Pred-
nisolone dose and the number of cases using im-
munosuppressants were not different between re-
lapsing and stable cases (Table 2). Immunosuppressants
were cyclophosphamide in 1 case, cyclosporine in 3
cases, methotrexate in 2 cases, and azathioprine in 2
cases.
The max SUV was higher in untreated (median
value, 2.8 [2.4 to 3.2]) and relapsing on treatment
cases (median value, 2.6 [2.3 to 3.3]) than in stable
on treatment cases (median value, 1.9; p 0.004 vs.
untreated; p  0.001 vs. relapsing) (Fig. 3). The
CRP levels and ESR showed same differences
among groups, but ESR did not show difference
between relapsing and stable cases (Fig. 4, right).
Correlations between max SUV and CRP or
ESR (r  0.646; p  0.001 vs. CRP, r  0.378;
p  0.018 vs. ESR) were significant (Fig. 5).
Table 3. Arteries of Highest Maximum Standardized Uptake Va
Active Inactive
Number of
Cases %
Number of
Cases %
Ascending aorta 5 18.5 1 8.3
Aortic arch 10 37.0 6 50.0
Descending aorta 0 0.0 0 0.0
Left carotid artery 4 14.8 2 16.7
Left subclavian artery 4 14.8 2 16.7
Brachiocephalic artery 1 3.7 1 8.3
Right carotid artery 1 3.7 0 0.0
Right subclavian artery 1 3.7 0 0.0
Left renal artery 1 3.7 0 0.0
3.0
2.5
2.0
1.5
1.0
0.5
TB
R
Active Inactive Control
p<0.001
p<0.001 n.s.
, and Control Cases
background ratio (TBR) (right) in active cases were statisticallylue
Control
Number of
Cases %
18 45.0
19 47.5
3 7.5
0 0.0
0 0.0
0 0.0
0 0.0
0 0.0ctive
et to
between u
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426Correlation coefficient between max SUV and ESR
was relatively low.
Comparisons of ROC curves between relapsing
and stable cases showed AUC to be 94.1% for max
SUV, 79.4% for CRP, and 63.2% for ESR. Max
SUV showed significant superiority to both CRP
100
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Se
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100-Specificity
1
0 20 40 60 80 100
Active and Inactive
max SUV T
Figure 2. Comparisons of Receiver-Operating Characteristic Cur
(Left) to detect active cases, the area under the curve (AUC) in max
ground ratio (TBR) (AUC: 91.4%) were superior to that in C-reactive
differentiate relapsing on treatment cases from stable on treatment
that in CRP and ESR.
6
5
4
3
2
1
Untreated
Active Inactive
Relapsing Stable
p<0.001
n.s. p<0.001
Comparisons of Max SUV Among Patients With Untreated,
on Treatment, and Stable on Treatment Takayasu Arteritis
s were divided into untreated and relapsing on treatment cases,
um standardized uptake value (max SUV) in the 2 groups were
ly higher than those in stable on treatment. The max SUV
ntreated and relapsing cases was not different.(p  0.0331) and ESR (p  0.0022) in ROC curve
analysis for determining recurrence (Fig. 2, right).
Representative cases of untreated and relapsing
cases are shown in Figures 6 and 7.
D I S C U S S I O N
We used FDG-PET/CT to assess TA disease
activity, because this modality can identify sites of
accelerated metabolism indicative of an inflamma-
tory reaction, and max SUV can be used to quan-
titatively represent the degree of inflammation. Our
present results thus support the concept that max
SUV provides a valid means of comparing patients
with active and inactive TA. We examined whether
changes in blood glucose levels and venous mean
SUV would impact the validity of our arterial max
SUV data but found that these data did not differ
between active and inactive TA.
Webb et al. (5) were the first to report the
diagnostic accuracy of FDG-PET in 18 TA cases.
Their SE was 92%, and SP was 100%. Disease
activity was determined by a combination of clinical
symptoms of TA in this report. Kobayashi et al.
(10) were the first to establish a cutoff for max SUV
in their study of 14 TA patients. Their SE was
90.9%, and SP was 88.8%, but they defined active
disease as a clinical requirement for prednisolone.
Walter et al. (6) described the qualitative utility of
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42720) or TA (n  6), and the visual grade of FDG
ptake (grades I to III) correlated significantly with
oth CRP and ESR. The SE for pathological FDG
ptake in large vessels was 60.0%, and SP was
9.8%, but disease activity was not assessed. We
btained higher SE (92.6%) and SP (91.7%) in a
arger number (39) of TA patients, compared with
hese previous studies. In addition, our first study
im was to analyze ROC curves and thereby dem-
nstrate diagnostic utility with a max SUV cutoff of
.1 (AUC: 95.4%). The optimal max SUV cutoff
or assessing TA activity remains to be determined.
n a previous study (10), the cutoff was lower than
urs, because the definition of active cases differed
rom that used in our study. Herein, we propose a
utoff of 2.1 for max SUV on the basis of our
linical study employing a subjective definition of
A activity.
12
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p<0.001
p=0.02 p=0.007
Figure 4. Comparisons of CRP and ESR Among Patients With Un
Takayasu Arteritis
C-reactive protein (CRP) was statistically different among untreated
(ESR) in relapsing and stable cases was not statistically different (rig
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y = 0.141x + 2.313
R2 = 0.417
Figure 5. Correlation With Max SUV to CRP and ESRCorrelation with max SUV to CRP and ESR is shown. Max SUV showed gooThe major challenge in therapeutic management
f TA is recurrence, because even if corticosteroid
herapy is effective, 72% of cases suffer multiple
ecurrences within 6 months (11). Conventional
nflammatory markers such as ESR and CRP,
hich reflect systemic inflammation, are nonspe-
ific for TA, and immunomodulatory agents can
odify these parameters. We focused on 2 groups
f acute TA patients: untreated, and relapsing on
reatment. In our evaluation of relapsing cases,
OC curves revealed that ESR and CRP underes-
imate TA activity in patients receiving steroid
reatment. Conversely, max SUV from FDG-
ET/CT showed a stronger correlation with clini-
al activity even in relapsing on treatment cases,
robably because FDG-PET/CT can detect local
nflammatory lesions in vessels. In addition, our
epresentative relapsing patient (Case 2) showed that
p=0.004
Untreated
Active
Relapsing
140
120
100
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40
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ES
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hr
)
Stable
p=0.001
n.s.
ated, Relapsing on Treatment, and Stable on Treatment of
psing, and stable cases (left). Erythrocyte sedimentation rate
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y = 0.008x + 2.201
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, relad correlation to CRP but not to ESR. Abbreviations as in Figure 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 4 , 2 0 1 2
A P R I L 2 0 1 2 : 4 2 2 – 9
Tezuka et al.
Sensitive Detection of Recurrence
428Figure 6. Representative Case #1 (Untreated Takayasu Arteritis)
A 20-year-old woman presented with left arm pain. The CRP and ESR were elevated to 11.04 mg/dl and 132 mm/h, respectively. Mag-
netic resonance (MR) angiography (top, middle) showed stenosis in the bilateral carotid and left subclavian arteries and diagnosed as
Takayasu arteritis. The 18F-ﬂuorodeoxyglucose uptake was seen in the same lesions and the aortic arch (bottom). She was classiﬁed as
untreated in this study. The measured max SUV in the aortic arch was highest level. She was administered corticosteroids. CT  com-
puted tomography; PET  positron emission tomography; other abbreviations as in Figure 2.Figure 7. Representative Case #2 (Relapsing on Treatment Takayasu Arteritis)
A 23-year-old woman with Takayasu arteritis was taking corticosteroids at a dose of 5 mg/day. The ESR was 18 mm/h, but she had left
arm pain with slight CRP elevation up to 1.1 mg/dl. The 18F-ﬂuorodeoxyglucose-PET/CT imaging showed uptake in the left subclavian
artery, and max SUV was elevated (left). After increasing dose of prednisolone to 30 mg/day, the uptake disappeared, and max SUV was
decreased (right). Strong 18F-ﬂuorodeoxyglucose uptake on her right side is uptake due to an artiﬁcial graft, from the right axial artery to
the right external iliac artery. Abbreviations as in Figures 2 and 6.
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429max SUV clearly represents therapeutic effectiveness
before versus after steroid treatment.
On the basis of these results, we recommend
imaging by FDG-PET for diagnosis of TA or
detection of its recurrence but not for routine
observation. This imaging could be useful, espe-
cially if the assessment of recurrence is difficult due
to absence or low levels of CRP or ESR elevation.
Study limitations. We performed FDG-PET/CT
and MR angiography or CTA not by prospective
protocol but by clinical needs in each case. The data
acquisition of the biomarkers was within 3 days of
FDG-PET/CT but not at the same time. Our pro-
tocol of FDG-PET was not optimized for measuring
vascular SUV, because of a relatively lower dose of
tracer and a shorter circulation time. The wall imaging
is important for diagnosing TA; however, we did not
perform wall imaging by MR in all patients in this
series. Comparisons of PET imaging and MR wall
imaging are a future issue of investigation.
C O N C L U S I O N S
Max SUV obtained with FDG-PET/CT had highA, et al. The role of 18F-FDG PET in 2009;60:1193–200.ROC curve indicated this approach to be superior
to both ESR and CRP, with statistical significance.
The diagnostic accuracy of max SUV was also
shown in relapsing TA cases. This technology
would allow differentiation of not only active TA
but also relapsing TA while receiving steroid ther-
apy from stable TA. In addition, FDG-PET/CT is
useful for localization of inflammation in TA.
We propose a max SUV cutoff of 2.1 for detect-
ing active inflammation of TA in untreated and
relapsing cases. The max SUV from FDG-
PET/CT allows sensitive assessment of clinical
state and facilitates selecting the optimal therapy for
TA patients.
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